20
Participants
Start Date
March 1, 2025
Primary Completion Date
March 1, 2027
Study Completion Date
September 1, 2027
Sacituzumab Govitecan (SG)
After enrollment, before subjects receive TROP-2 ADC treatment, after 2 cycles of treatment, and at the time of progression, in these three phases, subjects will undergo 89Zr-DFO-hSR7 and 18F-FDG examinations once respectively (subjects will first undergo the 18F-FDG examination, and then the 89Zr-DFO-hSR7 examination within 1 week).
RECRUITING
Beijing Cancer Hospital, Beijing
Peking University Cancer Hospital & Institute
OTHER